


## CLAIMS

1. A compound represented by formula (1):



wherein X is a sulfur atom or an oxygen atom;

R<sup>1</sup> and R<sup>2</sup> are independently a group represented by the formula: -Y<sup>3</sup>-Z, or R<sup>1</sup> and R<sup>2</sup>, when taken together, represent a substituted or unsubstituted alkylene group (the -CH<sub>2</sub>- groups of the alkylene group may be replaced by one or more substituents which may be the same or different and are selected from groups represented by the formulas: -O-, -S(O)<sub>n</sub>-, -N(R<sup>11</sup>)- and -C(=O)-);

Y<sup>3</sup> is a single bond or a substituted or unsubstituted alkylene group (the -CH<sub>2</sub>- groups of the alkylene group may be replaced by one or more substituents which may be the same or different and are selected from groups represented by the formulas: -O-, -S(O)<sub>n</sub>-, -N(R<sup>11</sup>)- and -C(=O)-, substituted or unsubstituted benzene rings, and substituted or unsubstituted cycloalkane rings);

Y<sup>1</sup> and Y<sup>2</sup> are independently a substituted or unsubstituted alkylene group (the -CH<sub>2</sub>- groups of the alkylene group may be replaced by one or more

substituents which may be the same or different and are selected from groups represented by the formulas:  $-O-$ ,  $-S(O)_n-$ ,  $-N(R^{11})-$  and  $-C(=O)-$ , substituted or unsubstituted benzene rings, and substituted or unsubstituted cycloalkane rings, provided that the end of the alkylene group directly bonded to each nitrogen atom in formula (1) is not a group represented by the formula:  $-N(R^{11})-$ ;

the  $-CH_2-$  groups in a cycloalkane ring in the case of the cycloalkane ring being present in any of  $Y^1$ ,  $Y^2$  and  $Y^3$  may be replaced by one or more substituents which may be the same or different and are selected from groups represented by the formulas:  $-O-$ ,  $-S(O)_n-$ ,  $-N(R^{11})-$  and  $-C(=O)-$ ;

any adjacent two carbon atoms of an alkylene group may form a double bond or a triple bond in the case of the alkylene group being present as any of  $Y^1$ ,  $Y^2$  and  $Y^3$  or in the case of  $R^1$  and  $R^2$  being taken together to represent the alkylene group;

$Z$  is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic heterocyclic group (these groups may be unsubstituted or substituted) or is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a

substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, or a group represented by the formula:  $-OR^{21}$ ,  $-N(R^{22})R^{23}$ ,  $-C(=O)OR^{21}$ ,  $-S(O)_nR^{24}$ ,  $-C(=O)R^{25}$ ,  $-C(=O)N(R^{22})R^{23}$ ,  $-N(R^{26})C(=O)R^{25}$ ,  $-S(O)_2N(R^{22})R^{23}$ ,  $-N(R^{26})S(O)_nR^{24}$  or  $-N(R^{26})C(=O)OR^{21}$ ;

M is a group represented by the formula:  $-C(=O)OR^{31}$ ,  $-S(O)_nOR^{31}$ ,  $-C(=O)N(R^{32})R^{33}$ ,  $-S(O)_nN(R^{32})R^{33}$  or  $-N(R^{34})S(O)_nR^{35}$ , a tetrazol-5-yl group, a 1,2,4-triazol-3-yl group, a 1,2,4-triazol-5-yl group, an imidazol-2-yl group or an imidazol-4-yl group;

Q is taken together with the group represented by the formula:  $-C=C-$  to which Q is bonded, to represent a benzene ring or a 5- or 6-membered heteroaromatic ring (these rings may be unsubstituted or substituted);

A is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic heterocyclic group (these groups may be unsubstituted or substituted);

$R^{11}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ ,  $R^{26}$ ,  $R^{31}$ ,  $R^{32}$ ,  $R^{33}$ ,  $R^{34}$  and  $R^{35}$ , which may be the same or different, are independently as follows (when any of them is present as two or more substituents, these substituents are independently as follows): a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or

unsubstituted cycloalkyl group or a substituted or unsubstituted aralkyl group, each of a combination of R<sup>22</sup> and R<sup>23</sup> and a combination of R<sup>32</sup> and R<sup>33</sup> being able to be taken together with the nitrogen atom to which the combination is bonded, to represent a saturated 3- to 8-membered cyclic amino group which may contain other heteroatoms in the ring (said cyclic amino group may be unsubstituted or substituted), provided that each of R<sup>24</sup> and R<sup>35</sup> is not a hydrogen atom when the number of oxygen atoms (n) on the sulfur atom bonded to R<sup>24</sup> or R<sup>35</sup>, respectively, is 1 or 2; and

n is 0, 1 or 2 (when n is present as two or more suffixes, these suffixes are independently 0, 1 or 2),

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

2. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1, wherein X is a sulfur atom.

3. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1 or 2, wherein Y<sup>2</sup> is a group represented by the formula: -S(O)<sub>2</sub>-, -C(=O)- or -CH<sub>2</sub>-.

4. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1, 2 or 3, wherein Q is taken together with the group represented by the

formula:  $-C=C-$  to which Q is bonded, to represent an unsubstituted or substituted o-phenylene group.

5. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 4, wherein M is a group represented by the formula:  $-C(=O)OR^{31}$ .

6. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 5, wherein  $Y^1$  is a substituted or unsubstituted  $C_{1-6}$ alkylene group.

7. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 6, wherein  $R^2$  is hydroxyl group, a cyano group, a halogen atom or an unsubstituted  $C_{1-6}$ alkyl group.

8. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 7, wherein A is a 1-naphthyl group or a 2-naphthyl group.

9. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 8, wherein in one or both of  $R^1$  and  $R^2$ , Z is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic heterocyclic group, and each of these groups

is substituted by a group represented by the formula: -  
 $Y^4-Z'$  in which

$Y^4$  is a single bond or a substituted or unsubstituted alkylene group (the  $-\text{CH}_2-$  groups of the alkylene group may be replaced by one or more substituents which may be the same or different and are selected from groups represented by the formulas:  $-\text{O}-$ ,  $-\text{S}(\text{O})_n-$ ,  $-\text{N}(\text{R}^{11})-$  and  $-\text{C}(=\text{O})-$ , substituted or unsubstituted benzene rings, and substituted or unsubstituted cycloalkane rings (the  $-\text{CH}_2-$  groups in the cycloalkane ring may be replaced by one or more substituents which may be the same or different and are selected from groups represented by the formulas:  $-\text{O}-$ ,  $-\text{S}(\text{O})_n-$ ,  $-\text{N}(\text{R}^{11})-$  and  $-\text{C}(=\text{O})-$ ), and any adjacent two carbon atoms of the alkylene group may form a double bond or a triple bond);

$Z'$  is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic heterocyclic group (each of these groups may be either unsubstituted or substituted by one or more substituents which may be the same or different and are selected from halogen atoms, nitro group, cyano group, alkyl groups, aralkyl groups, alkoxy groups and alkylenedioxy groups); and

$\text{R}^{11}$  and  $n$  are as defined above (when either of them is present as two or more substituents or

suffixes, respectively, these substituents or suffixes are independently as defined above).

10. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 9, wherein  $Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  are independently a group represented by the formula:  $-(CH_2)_p-(CH_2)_q-$ ,  $-(CH_2)_p-O-(CH_2)_q-$ ,  $-(CH_2)_p-S(O)_n-(CH_2)_q-$ ,  $-(CH_2)_p-N(R^{11})-(CH_2)_q-$ ,  $-(CH_2)_p-C(=O)N(R^{11})-(CH_2)_q-$ ,  $-(CH_2)_p-N(R^{11})C(=O)-(CH_2)_q-$ ,  $-(CH_2)_p-C(=O)O-(CH_2)_q-$ ,  $-(CH_2)_p-OC(=O)(CH_2)_q-$ ,  $-(CH_2)_p-SO_2N(R^{11})-(CH_2)_q-$ ,  $-(CH_2)_p-N(R^{11})SO_2-(CH_2)_q-$  or  $-(CH_2)_p-R^{12}-(CH_2)_q-$ , which may be substituted or unsubstituted and in which each of p and q is such an integer that p + q is 0 to 6,  $-(CH_2)_p-$  may form a double bond or a triple bond between its adjacent carbon atoms in the case of p being 2 or more, and  $-(CH_2)_q-$  may form a double bond or a triple bond between its adjacent carbon atoms in the case of q being 2 or more; and

$R^{12}$  is a substituted or unsubstituted benzene ring, or a substituted or unsubstituted cycloalkane ring.

11. A pharmaceutical composition comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 10.

12. A chymase inhibitor comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of

claims 1 to 10.

13. A pharmaceutical composition for the treatment of hypertension, cardiac failure, ischemic peripheral circulatory disturbance, myocardial ischemia, venous malfunction, cardiac failure advance after myocardial infarction, diabetic nephropathy, nephritis, arteriosclerosis, hyperaldosteronism, scleroderma, glomerulosclerosis, renal failure, central nervous system diseases, Alzheimer's disease, hypomnesia, depression, sensory functional disorders, anxiety, tension, unpleasant mental condition, glaucoma, ocular hypertension, restenosis after PTCA, asthma, rhinitis, COPD or allergic diseases, which comprises a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 10.